SLCO1B3 and cancer: By using primers that discriminate between liver- and cancer-type variants, we were able to demonstrate that Ct-SLCO1B3 transcripts were significantly expressed in RDEB-SCC cell lines and patient tumor biopsies as compared with non-tumor RDEB or normal human keratinocyte cell lines, making this variant transcript a potential therapeutic target as well in this tumor entity.